Simvatstatin Used to Treat Pulmonary Hypertension - Full Text View

Sponsor:	Capital Medical University
Information provided by:	Capital Medical University
ClinicalTrials.gov Identifier:	NCT00538044

Purpose

we try to use simvastatin in the treatment of advanced pulmoary hypertension secondary to congenital heart disease or chronic pulmonary embolism before and after the operation.

Condition	Intervention	Phase
Hypertension, Pulmonary	Drug: simvastatin	Phase I

Study Type:	Interventional
Study Design:	Treatment, Randomized, Single Blind (Investigator), Placebo Control, Parallel Assignment
Official Title:	the Clinical Research Using Simvastatin as a Medication to Treat Advanced Secondary Pulmonary Hypertension

Resource links provided by NLM:

MedlinePlus related topics: Heart Diseases High Blood Pressure Pulmonary Embolism Pulmonary Hypertension

Drug Information available for: Simvastatin

U.S. FDA Resources

Further study details as provided by Capital Medical University:

Primary Outcome Measures:

the simvastatin can alleviate pulmonary hypertension
pulmonary pressure

Secondary Outcome Measures:

simvastatin can highten the perioperative and long term survaval rate and the living quality

Study Start Date:	January 2009
Estimated Study Completion Date:	January 2012

Arms	Assigned Interventions
1simvastatin group: Experimental before the operation, the patient start the simvastatin medication on the dosage of 40mg per day	Drug: simvastatin medication with simvastation on the dosage of 40mg per day before the operation and all the time after the operation
2contral group: No Intervention just do routin operation with no use of simvastatin, other medication is exact the same as the simvastatin group

Detailed Description:

advanced pulmonary hypertension is refractory to the medication in use nowaday, especially pulmonary hypertension secondary to congenital heart disease or chronic pulmonary embolism.It is revealed that statins may intefere the pathogenisis of the pulmonary hypertension in many key poing, such as improving apotosis or inhiting the proliferation of pulmonary vascular smooth muscle cell. so we try to use simvastatin in the treatment of advanced pulmoary hypertension secondary to congenital heart disease or chronic pulmonary embolism before and after the operation.

Eligibility

Ages Eligible for Study:	12 Years to 70 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

pasp>50mmHg

Exclusion Criteria:

pasp<50mmhg

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00538044

Contacts

Contact: Huili Gan, MD,Ph.D.

13001277863

ganhuili@hotmail.com

Locations

China
Beijing Anzhen Hospital
Beijing, China, 100029

Sponsors and Collaborators

Capital Medical University

Investigators

Study Chair:

Huili Gan, MD,Ph.D.

Beijing Anzehn Hospital

More Information

No publications provided

Study ID Numbers:	Gan1, Anzhen1
Study First Received:	October 1, 2007
Last Updated:	October 1, 2007
ClinicalTrials.gov Identifier:	NCT00538044 History of Changes
Health Authority:	China: Ethics Committee

Keywords provided by Capital Medical University:

pulmonary hypertension
simvastatin
advanced pulmonary hypertension secondary to congenital heart disease
advanced pulmonary hypertension secondary to chronic pulmonary embolism

Additional relevant MeSH terms:

Antimetabolites
Molecular Mechanisms of Pharmacological Action
Simvastatin
Antilipemic Agents
Vascular Diseases
Enzyme Inhibitors
Anticholesteremic Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors

Pharmacologic Actions
Respiratory Tract Diseases
Hypertension, Pulmonary
Lung Diseases
Therapeutic Uses
Cardiovascular Diseases
Hypertension

ClinicalTrials.gov processed this record on February 08, 2010